NIDCD Core for Clinical Research and Care

NIDCD 临床研究和护理核心

• 批准号: 10470081
• 负责人: CARTER VAN WAES
• 金额: $ 254.1万
• 依托单位: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10470081
• 关键词: AQP1 gene; Adjuvant Study; Administrator; Admission activity; Adult; Affect; Ambulatory Care Facilities; Appointment; Area; Audiology; Care given by nurses; Caring; Child; Chromosome Mapping; Cisplatin; Clinical; Clinical Clerkship; Clinical Data; Clinical Investigator; Clinical Research; Clinical Services; Clinical Trials; Clinics and Hospitals; Communication; Communication impairment; Complex; Consult; Consultations; Continuing Education; Credentialing; Data; Data Collection; Databases; Development; Disease; Dose; Drug Kinetics; Emergency Situation; Endoscopy; Equilibrium; Equipment and Supplies; Evaluation; Fellowship; Fostering; Genes; Genetic study; Genomics; Head Cancer; Head and Neck Cancer; Head and Neck Disorder; Head and Neck Squamous Cell Carcinoma; Head and Neck Surgeon; Hearing; Hearing problem; Hereditary Disease; Hospital Administration; Hospitals; Hour; Human; Human Papilloma Virus Vaccine; Human Papillomavirus; Human Resources; Human papilloma virus infection; Image; Immune; India; Inpatients; Institutes; Institutional Review Boards; Intervention Studies; Intramural Research Program; Laboratories; Labyrinth; Maintenance; Malignant Neoplasms; Medical; Medical Students; Mentors; Mission; Molecular; Molecular Analysis; Monitor; NF-kappa B; National Institute on Deafness and Other Communication Disorders; Natural History; Neck Cancer; Nurse Practitioners; Nursing Research; Olfactory Neuroblastoma; Operative Surgical Procedures; Otolaryngologist; Otolaryngology; Outpatients; Pakistan; Parotid Gland; Pathogenesis; Patient Care; Patient Education; Patients; Phase; Phase I/II Trial; Phenotype; Physicians; Program Development; Proteomics; Protocols documentation; Provider; Records; Recurrence; Recurrent respiratory papillomatosis; Research; Research Support; Research Training; Resectable; Resources; Safety; Salivary; Scientist; Services; Signal Transduction; Solid Neoplasm; Specimen; Speech; Supervision; Surgeon; Syndrome; Testing; Time; Training; Transforming Growth Factor beta; Travel; Triad Acrylic Resin; United States National Institutes of Health; Vaccines; Vestibular Aqueduct; Visit; Voice; Work; adeno-associated viral vector; anti-PD-L1; anti-tumor immune response; atorvastatin; career development; chemotherapy; cisplatin induced hearing loss; clinical care; clinical implementation; data management; genetic analysis; genetic deafness; genome editing; hearing impairment; hearing restoration; hereditary hearing loss; human subject; inpatient service; irradiation; meetings; neoplasm therapy; outpatient programs; patient screening; phase 1 study; phase 2 study; programs; protocol development; quality assurance; recruit; response; symposium; transcription factor; volunteer

The NIDCD Core for Clinical Research and Care supports the following NIDCD projects: 1 Z01-DC-000016 NF-kappaB in the molecular pathogenesis and therapy of Neoplasms Affecting Human Communication 1 ZIA DC000039 Identification of Genes Causing Syndromic And Nonsyndromic Hearing Impairment 1 ZIA DC000046 Genetic Studies of Human Communications Disorders 1 ZIA DC000060 Molecular Analysis Of Human Hereditary Deafness 1 ZIA DC000064 Clinical Analysis Of Disorders Of Hearing And Balance 1 ZIA-DC-000073 Signal and Transcription Factor Network Interactions in Head and Neck Cancer 1 ZIA-DC-000074 Genomics and Proteomics of Head and Neck Cancer 1 ZIA-DC-000082 Neurotology Program 1 ZIA-DC-000087 Characterization & Enhancement of Anti-tumor Immune Responses in Head & Neck Cancer 1-ZIA-DC-000088 Cellular and Molecular Pathogenesis of Hearing Restoration in Adullt Inner Ear 1-ZIA-DC-000090 Mechanisms and Optimal Combination of Cisplatin Chemotherapy for Head and Neck Cancer The NIDCD and collaborative protocols supported by the core include: OH93-DC-0016 - Nonsyndromic Hereditary Hearing Impairment Gene Mapping: India / Pakistan Protocol 97-DC-0180 - Genetic Analysis of Human Hereditary Hearing Impairment 01-DC-0228 - Clinical and Molecular Analysis of Hearing Impairment with Enlarged Vestibular Aqueducts 01-DC-0229- Genetic Analysis of Hereditary Disorders of Hearing and Balance 17-DC-0138 - Cisplatin and statins in ototoxcity 18-DC-0051 - NIDCD Biospecimens protocol 20-DC-0047 Natural History and Genome Editing in Dominant Hearing Loss 21-DC-0002 Phase III Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss 21-C-0009 A Natural History Study of Children and Adults With Olfactory Neuroblastoma 000077 Clinical Data and Specimens in head and neck disorders 000141 Hearing Instability Phenotyping 15-D-0129 Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 in Irradiation-Induced Parotid Salivary Hypofunction 19-C-0041 Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma 19-C-0002 A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis 20-C-0024 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination with TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated with Human Papillomavirus Infection 20-C-0155 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetic , Immune and Clinical Activity of SX-682 in Combination with M7824 With CV301 TRICOM in Advanced Solid Tumors 20-C-0104 Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive Cancers 21-C-0013 A Phase I Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis The NIDCD Core for Clinical Research and Care supports over 3,000 outpatient clinic evaluations per year. Core otolaryngologists perform 50-100 major surgical cases annually. Staff mentor medical students during senior clinical clerkships. The Otolaryngologist Surgeon Scientist Career Development Program is coordinated through the OCD.

NIDCD临床研究和护理核心支持以下NIDCD项目： 1 Z01-DC-000016核因子-kappaB在影响人类沟通的肿瘤分子发病机制和治疗中的作用 1 Zia DC000039综合征性和非综合征性耳聋基因鉴定 1 Zia DC000046人类沟通障碍的遗传学研究 1人遗传性耳聋的Zia DC000060分子分析 1 Zia DC000064听力和平衡障碍临床分析 1头颈癌中ZIA-DC-000073信号和转录因子网络的相互作用 1头颈癌ZIA-DC-000074基因组学和蛋白质组学研究 1个ZIA-DC-000082神经病学项目 1-ZIA-DC-000087的特性及其增强头颈癌抗肿瘤免疫应答的研究 1-ZIA-DC-000088成人内耳听力恢复的细胞和分子机制 1-ZIA-DC-000090机制及顺铂治疗头颈癌的优化组合 核心支持的NIDCD和协作协议包括： OH93-DC-0016-非综合征遗传性耳聋基因图谱：印度/巴基斯坦方案 97-DC-0180-遗传性耳聋的遗传分析 01-DC-0228-前庭导水管扩大所致听力障碍的临床和分子分析 01-DC-0229-遗传性听力和平衡障碍的遗传分析 17-DC-0138-顺铂和他汀类药物耳毒性 18-DC-0051-NIDCD生物检疫协议 20-DC-0047遗传性耳聋的自然病史和基因组编辑 21-DC-0002阿托伐他汀降低顺铂所致听力损失的III期干预研究 21-C-0009儿童和成人嗅神经母细胞瘤的自然史研究 000077例头颈部疾病的临床资料和标本 000141听力不稳定表型 15-D-0129剂量递增研究评价单次注射携带人水通道蛋白-1基因的腺相关病毒载体治疗放射性腮腺功能减退的安全性 19-C-0041双适形调强再放疗治疗局部复发的头颈部鳞状细胞癌 19-C-0002复发性呼吸道乳头状瘤病患者M7824的II期研究 20-C-0024抗PD-L1/转化生长因子-β陷阱(M7824)单独及联合三联疫苗和N-803治疗与人乳头瘤病毒感染无关的可切除头颈部鳞状细胞癌 20-C-0155期试验研究SX-682联合M7824和CV301治疗晚期实体瘤的安全性、耐受性、药代动力学、免疫学和临床活性 HPV疫苗PRGN-2009单独或联合抗PD-L1/转化生长因子-β陷阱(M7824)治疗HPV阳性癌症的I/II期20-C-0104试验 21-C-0013佐剂PRGN-2012治疗成人复发性呼吸道乳头状瘤病的I期研究 NIDCD临床研究和护理核心每年支持3000多个门诊评估。耳鼻咽喉科核心医生每年要做50-100例大手术。在高级临床助理期间，工作人员指导医学生。耳鼻喉科外科科学家职业发展计划是通过强迫症协调的。